Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593271 | 1.00 | KMT2A (0.56) | KMT2AHTT | |
| SCHEMBL10020281 | 0.93 | HTT (0.62) | HTT | |
| SCHEMBL7786363 | 0.92 | — | — | |
| SCHEMBL21891729 | 0.92 | — | — | |
| SCHEMBL989310 | 0.92 | — | — | |
| SCHEMBL18389610 | 0.90 | — | — | |
| SCHEMBL988970 | 0.87 | — | — | |
| SCHEMBL3949450 | 0.86 | TAAR1 (0.54) | HTT | |
| SCHEMBL27843338 | 0.86 | HDAC1 (0.62) | — | |
| SCHEMBL9276339 | 0.86 | TAAR1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-10077284-B2 | UBA5 inhibitors | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2018-09-18 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20170107247-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-04-20 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2322515-B1 | A process for the preparation of an N-carboxy amino acid anhydride or an amino acid carbamate | JSR CORP (JP) | 2016-04-20 | — | — | EP | disclosed |
| WO-2015179955-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-8748650-B2 | Method for production of N-carboxy amino acid anhydride and amino acid carbamate compound | JSR CORPORATION (JP) | 2014-06-10 | — | — | US | disclosed |
| US-20110152561-A1 | METHOD FOR PRODUCTION OF N-CARBOXY AMINO ACID ANHYDRIDE AND AMINO ACID CARBAMATE COMPOUND | JSR CORPORATION (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2322515-A1 | N-CARBOXY AMINO ACID ANHYDRIDE AND AMINO ACID CARBAMATE COMPOUND PRODUCTION METHOD | JSR Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| EP-0000023-B1 | OMEGA-SUBSTITUTED PENTYL UREAS, THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1980-07-23 | — | — | EP | disclosed |
| US-4188401-A | Combating fungi with 1-(ω-substituted pentyl)-3-(2-cyano-acetyl)-ureas | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077284-B2 | UBA5 inhibitors | UBQLN2, UBTF, UBQLN1 | KMT2A 1906/4885HTT 1483/4885 |
| US-20110152561-A1 | METHOD FOR PRODUCTION OF N-CARBOXY AMINO ACID ANHYDRIDE AND AMINO ACID CARBAMATE COMPOUND | CA7, CPS1, DNPEP | KMT2A 1822/4885HTT 3119/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | KMT2A 4752/4885HTT 345/4885 |
| US-20170107247-A1 | UBA5 INHIBITORS | UBQLN2, UBTF, UBQLN1 | KMT2A 1906/4885HTT 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.